Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$162.20 USD

162.20
807,746

+0.53 (0.33%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $160.73 -1.47 (-0.91%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

Ekta Bagri headshot

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.

Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year

Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts

Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.

Incyte (INCY) Announces Positive Results From Vitiligo Study

Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate

Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.

Repligen (RGEN) Enters Oversold Territory

Repligen (RGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates

Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.

Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line

Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.

Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.

Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp

Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

Tirthankar Chakraborty headshot

5 of the Best Stocks to Buy Now for Striking Earnings Growth

Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss

Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.

Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 58.14% and 22.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.

Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.